Obesity and metabolic (bariatric) surgery

Roux-en-Y gastric bypass produces longer-lasting improvements in glycemic control than sleeve gastrectomy, despite similar initial rates of type 2 diabetes remission, shows a large real-world study.

People who undergo bariatric surgery are just as likely to achieve diabetes remission and reduce their risk for microvascular complications regardless of when they first became obese, suggest findings from the Swedish Obese Subjects study.

Late relapse of type 2 diabetes is relatively common after bariatric surgery, but does not negate the metabolic health benefits of the procedure, a study shows.

Adolescents who undergo bariatric surgery do not as a rule experience resolution of mental health problems, say researchers.

Swedish research suggests that determining type 2 diabetes duration prior to bariatric surgery could help prioritize those patients most likely to achieve diabetes remission.

People with obesity and type 2 diabetes who undergo gastric bypass surgery have higher rates of diabetes remission after 1 year than those undergoing sleeve gastrectomy, indicate findings from the Oseberg trial.

People with type 2 diabetes and obesity who undergo metabolic surgery have a significantly lower risk for major adverse cardiovascular events than those who do not receive surgery, observational study data show.

Individuals with lower preoperative levels of serum succinate are more likely to achieve remission of type 2 diabetes after bariatric surgery than those with higher levels of the metabolite, study results suggest.

People who undergo bariatric surgery have a lower long-term risk for mortality, but a higher risk for adverse events such as gastrointestinal and nutritional disorders, compared with those who do not undergo surgery, researchers report.

Read the linked commentary from John Wilding

Findings from the GRAVITAS trial indicate that use of the GLP-1 receptor agonist liraglutide alongside a diet and physical activity intervention may improve glycemic control among people with persistent or recurrent type 2 diabetes after bariatric surgery.

Adolescents who undergo bariatric surgery are more likely than adult patients to have remission of diabetes and hypertension, but require more reoperations, show the 5-year outcomes of the Teen-LABS cohort.

Findings from the YOMEGA trial indicate that the one anastomosis gastric bypass procedure is noninferior to standard Roux-en-Y gastric bypass in terms of weight loss and metabolic outcomes.

Almost three-quarters of patients who undergo Roux-en-Y gastric bypass experience diabetes remission within 1 year of surgery, but nearly one-third subsequently relapse, population-based study data show.

Overweight and obese patients with type 2 diabetes who undergo gastric bypass have significantly lower risks for death, cardiovascular disease, and severe kidney disease than those who do not have such surgery, Swedish research shows.

Patients undergoing Roux-en-Y gastric bypass experience significantly greater weight loss for at least 5 years than those undergoing sleeve gastrectomy and adjustable gastric banding, but are at greater risk for adverse events, research shows.

An observational study published in JAMA demonstrates a substantial reduction in the risk for hard cardiovascular endpoints in obese patients with type 2 diabetes who have undergone bariatric surgery.

The results of the adult surgery study from the RISE consortium show that gastric banding has only a small effect on the deterioration of beta-cell function relative to metformin, despite causing markedly greater weight loss.

A novel scoring system that could be used in routine clinical care can predict remission from type 2 diabetes 5 years after gastric bypass surgery, researchers report.

Obese patients with type 2 diabetes who undergo bariatric surgery achieve large reductions in their risk for microvascular complications, shows a real-world study.

Gastric bypass surgery benefits obese patients with type 2 diabetes in many ways, but such benefits come at a cost, show data presented at the ADA’s 78th Scientific Sessions in Orlando, Florida.